Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction.
about
Antibiotics for secondary prevention of coronary heart diseaseLack of association between Chlamydia Pneumoniae serology and endothelial dysfunction of coronary arteriesBiophysical regulation of Chlamydia pneumoniae-infected monocyte recruitment to atherosclerotic foci.Interference of antibacterial agents with phagocyte functions: immunomodulation or "immuno-fairy tales"?Fungal rDNA signatures in coronary atherosclerotic plaques.Genomic approach for analysis of surface proteins in Chlamydia pneumoniaeC-reactive protein as a predictor of improvement and readmission in heart failure.Higher incidence of persistent chronic infection of Chlamydia pneumoniae among coronary artery disease patients in India is a cause of concern.Chlamydia pneumoniae and atherosclerosis.Chlamydia pneumoniae in arteries: the facts, their interpretation, and future studies.Is cardiovascular disease preventable by vaccination?Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart diseaseChlamydia pneumoniae and coronary heart disease.The anti-inflammatory effects of macrolides.Pathogenic mechanisms in unstable anginaManagement of unstable angina based on considerations of aetiologyAntimicrobial therapy for Chlamydia pneumoniae: its potential role in atherosclerosis and asthma.Effect of clarithromycin treatment on Chlamydia pneumoniae in vascular tissue of patients with coronary artery disease: a randomized, double-blind, placebo-controlled trialLocal immune responses to Chlamydia pneumoniae in the lungs of BALB/c mice during primary infection and reinfectionMacrolide antibiotics and the risk of cardiac arrhythmiasRecent advances. General medicine.Effects of serine/threonine protein phosphatases on ion channels in excitable membranes.Helicobacter pylori, Chlamydia pneumoniae, and cytomegalovirus: chronic infections and coronary heart disease.Chlamydial and human heat shock protein 60s activate human vascular endothelium, smooth muscle cells, and macrophages.Recent Advances in the Prevention of Coronary Artery Diseases: Focus on Primary Prevention.Atherosclerosis, inflammation, and infection.Inflammation, infection and atherosclerosis: do antibacterials have a role in the therapy of coronary artery disease?The antimicrobial treatment of periodontal disease: changing the treatment paradigm.Chlamydia pneumoniae in atherosclerosis.Chlamydia pneumoniae and atherosclerosis: critical assessment of diagnostic methods and relevance to treatment studiesInfections and atherosclerosis.The unfolding story of the chaperonins.Background and current knowledge of Chlamydia pneumoniae and atherosclerosis.Polymerase chain reaction detection of Chlamydia pneumoniae in circulating white blood cells.Antibiotics in the prevention and treatment of coronary heart disease.Inflammation, infection, or both in atherosclerosis: the ROXIS trial in perspective.Collaborative multidisciplinary workshop report: clinical antimicrobial trials for primary and secondary prevention of atherosclerotic cardiovascular disease.Role of infectious and immune factors in coronary and cerebrovascular arteriosclerosisAtherosclerosis: an infectious disease?Effect of azithromycin plus rifampin versus amoxicillin alone on eradication and inflammation in the chronic course of Chlamydia pneumoniae pneumonitis in mice
P2860
Q24201388-D33AA6B7-F4B4-401A-8329-9459DBB66142Q24802081-F9495E6E-47B6-443A-B17A-2513785D7944Q27302171-A74F4899-A759-40D3-A8B7-B37975D54FC8Q30327329-B677D542-35A4-42D3-B809-F931687BE1B4Q30835828-6FE09DDB-E153-4DA4-A67F-3B8686A27FCAQ31032708-3C5013A4-ED80-49F3-959A-FAB05DAD1AA5Q33147741-697DF31B-2A93-4CF9-B4EB-4BDF6049A71CQ33286200-1D68C558-1B7E-46D3-AC8F-4E6AF0C5DC4DQ33534714-E432D8A3-37A7-46FB-BB67-2759B47B577EQ33588103-EFC80EC0-8008-4DE3-91DE-5230EFAE4939Q33603398-08D145AC-25E0-41B1-95AB-CB7BB9A42C48Q33646625-8BEA5139-42BE-48C2-A304-8683D0F86F46Q33659387-44717503-DE75-4D40-8353-FB2D1B83AE32Q33714051-5B2ACC99-0955-4626-A9C2-3C0C645F6231Q33723960-6F899552-15C7-44FB-BBA3-570E3A68D415Q33723966-5D71FF9F-69EB-416E-BCEB-3AB00FB1BF66Q33726287-C1538EA1-7B9E-4E6A-9E2D-B50932F68773Q33752851-4510664D-0714-4F08-AC6A-5BF6424F09A8Q33767275-E2E8C465-B4E2-4051-B7F1-089980AD6CA7Q33772270-B796B863-7084-47C8-A78F-6DE77B2DEBD6Q33791941-865C6D3B-8F72-448E-BA1B-AA25EF381B0FQ33807200-9EB48CC5-E68A-44B2-8D1D-1033A5B20A00Q33821315-A8EB81B2-C7E0-4BC6-BD1D-10196DF48876Q33842925-8FF95629-8942-4AC1-B681-59C900BC595BQ33843402-67449FF4-5851-4B07-86AE-12349CEFB639Q33843534-0B501259-EBE9-4C39-9DC0-62595B49700DQ33871329-9233B5B6-E465-4C6A-935F-C63F7B773054Q33888246-D86257E1-9D37-42B2-8EBA-94F0573A8DB6Q33890410-76723C60-899F-44F6-B744-D468A5F28DFDQ33905858-4EB9732A-1531-4493-8F38-0C641B2D1D08Q33921219-0A32E642-FD1E-48AC-852A-0B4253167667Q33923440-EF5E7C80-5FD5-40F7-B510-18645F7515C2Q33935003-9336FF95-F180-48A8-90A6-FFFC4EF7FD9EQ33935030-6EA1623B-8997-4263-93C5-116C73AFFF1EQ33935098-7B56A4B1-2CE9-4EBC-BC70-0C496B523EE9Q33935103-DED93669-E617-4193-ABCC-74CA4A6DDD78Q33935109-2BE8B873-512E-409E-8ADB-AA7723865F99Q33942966-202476A5-A230-4F16-961B-41CD3FE3C7CAQ33972834-362335BE-9C17-45FC-AFE0-98F6622B1A3FQ33979917-9A88FE39-C05C-4974-9457-34F4B678DE75
P2860
Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 1997
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Elevated Chlamydia pneumoniae ...... vors of myocardial infarction.
@en
Elevated Chlamydia pneumoniae ...... vors of myocardial infarction.
@nl
type
label
Elevated Chlamydia pneumoniae ...... vors of myocardial infarction.
@en
Elevated Chlamydia pneumoniae ...... vors of myocardial infarction.
@nl
prefLabel
Elevated Chlamydia pneumoniae ...... vors of myocardial infarction.
@en
Elevated Chlamydia pneumoniae ...... vors of myocardial infarction.
@nl
P2093
P921
P356
P1433
P1476
Elevated Chlamydia pneumoniae ...... vors of myocardial infarction.
@en
P2093
P304
P356
10.1161/01.CIR.96.2.404
P407
P577
1997-07-01T00:00:00Z